In a study of patients with advanced melanoma receiving immunotherapy (anti-CTLA4, anti-PD1, or combination therapy) (34), they reported a significant decrease in circulating B cells in the combination therapy cohort, but not in patients receiving anti-CTLA4 or anti-PD1 therapy. This evidence concerns the gene CTLA4 and melanoma.